AR031536A1 - Analogos heteroatomo- interrumpidos del acido 15-hidroxieicosatetraenoico, composicion que lo comprende y el uso de los mismos para la manufactura de un medicamento - Google Patents
Analogos heteroatomo- interrumpidos del acido 15-hidroxieicosatetraenoico, composicion que lo comprende y el uso de los mismos para la manufactura de un medicamentoInfo
- Publication number
- AR031536A1 AR031536A1 ARP000105867A ARP000105867A AR031536A1 AR 031536 A1 AR031536 A1 AR 031536A1 AR P000105867 A ARP000105867 A AR P000105867A AR P000105867 A ARP000105867 A AR P000105867A AR 031536 A1 AR031536 A1 AR 031536A1
- Authority
- AR
- Argentina
- Prior art keywords
- same
- different
- functionally modified
- pharmaceutically acceptable
- free
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se revelan análogos hetero-átomos-interrumpidos del ácido 15-hidroxieicosatetraenoico, que comprenden un compuesto de la siguiente formula (1): en la cual: R1 es CO2R, CONR2R3, CH2OR4, CH2NR5R6, CH2N3, CH2-Hal, CH2NO2, CH2SR20, COSR21 o 2, 3, 4, 5 ûtetrazol-1-ilo, en el cual: R representa H, o CO2R forman una sal farmacéuticamente aceptable o un éster farmacéuticamente aceptable; NR2R3 y NR5R6, que son iguales o diferentes, comprenden un grupo amino libre o funcionalmente modificado; OR4 comprende un grupo hidroxi libre o funcionalmente modificado; Hal es F, Cl, Br, o l; SR20 comprende un grupo tiol libre o funcionalmente modificado; R21 es H, o COSR21 forman una sal farmacéuticamente aceptable o un tioéster farmacéuticamente aceptable; K es alquilo de C2-8, alquenilo, alquinilo, o un grupo allenilo de C3-8; A y X , que comprende ser iguales o diferentes, son un enlace directo CH2, NR7, O o S, con la condicion que por lo menos uno de A y X, es NR7, O, o S; B es H, o BB juntos comprenden un O, S o NR8 doblemente enlazado, con la condicion que BB comprende un O; S o NR8 doblemente enlazado cuando A y X son iguales o diferentes y son NR7, O o S; en lo cual: NR7 y NR8 son iguales o diferentes y comprenden un grupo amino funcionalmente modificado; p vale 0 o 1; D û E y G ûH, son iguales o diferentes y son CH2CH2, CH=CH o C:::C; e Y es C(O), o Y es formula (2) en lo cual R9O constituyen un grupo hidroxi libre o funcionalmente modificado, con la condicion que se excluya el siguiente compuesto de formula (3), composicion que los comprende y el uso de los mismos para la manufactura de un medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16438399P | 1999-11-09 | 1999-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031536A1 true AR031536A1 (es) | 2003-09-24 |
Family
ID=22594245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105867A AR031536A1 (es) | 1999-11-09 | 2000-11-08 | Analogos heteroatomo- interrumpidos del acido 15-hidroxieicosatetraenoico, composicion que lo comprende y el uso de los mismos para la manufactura de un medicamento |
Country Status (20)
Country | Link |
---|---|
US (3) | US6331566B1 (es) |
EP (1) | EP1227809B1 (es) |
JP (1) | JP2003513910A (es) |
KR (1) | KR20020040848A (es) |
CN (1) | CN1382046A (es) |
AR (1) | AR031536A1 (es) |
AT (1) | ATE292464T1 (es) |
AU (1) | AU776258B2 (es) |
BR (1) | BR0015423A (es) |
CA (1) | CA2386623A1 (es) |
DE (1) | DE60019322T2 (es) |
ES (1) | ES2235966T3 (es) |
HK (1) | HK1045260B (es) |
MX (1) | MXPA02004702A (es) |
PL (1) | PL356092A1 (es) |
PT (1) | PT1227809E (es) |
TR (1) | TR200201249T2 (es) |
TW (2) | TWI268776B (es) |
WO (1) | WO2001034129A2 (es) |
ZA (1) | ZA200202278B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030109508A1 (en) * | 2001-10-11 | 2003-06-12 | Alcon, Inc. | Methods for treating dry eye |
WO2003030892A1 (en) * | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
US20030232858A1 (en) * | 2002-06-14 | 2003-12-18 | Barker Ronnie C. | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
AU2003221707A1 (en) * | 2002-06-14 | 2003-12-31 | Alcon, Inc. | Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis |
EP1583527A1 (en) * | 2002-06-14 | 2005-10-12 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders |
PL374700A1 (en) * | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
KR102062824B1 (ko) * | 2006-09-13 | 2020-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸]-4-플루오로-벤조니트릴의 용도 |
ITUB20153104A1 (it) * | 2015-08-13 | 2017-02-13 | Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm | Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti |
CN111937121B (zh) * | 2018-04-04 | 2023-12-08 | 巴斯夫欧洲公司 | 在制造半导体基材的方法中使用的可裂解添加剂 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991759A (en) | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4370325A (en) | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
AU546872B2 (en) | 1982-06-16 | 1985-09-26 | Unilever Plc | Skin treatment compositions containing a fatty acid or ester |
US4421748A (en) | 1982-07-13 | 1983-12-20 | Trager Seymour F | Artificial tear aid |
GB8319073D0 (en) | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
US4868154A (en) | 1986-02-19 | 1989-09-19 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with melanocyte stimulating hormones |
US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
US4744980A (en) | 1986-04-28 | 1988-05-17 | Holly Frank J | Ophthalmic solution for treatment of dry eye syndrome |
US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
US4818537A (en) | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
US4921644A (en) | 1988-02-29 | 1990-05-01 | Technology Unlimited, Inc. | Mucin directed lipsome |
US4906467A (en) * | 1988-03-24 | 1990-03-06 | New York Medical College | Novel, long-duration treatment for glaucoma |
US4923700A (en) | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Artificial tear suspension |
US5064655A (en) | 1989-02-24 | 1991-11-12 | Liposome Technology, Inc. | Liposome gel composition and method |
US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
AU655919B2 (en) | 1990-02-22 | 1995-01-19 | Macnaught Pty Limited | Artificial tears |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
ATE132366T1 (de) | 1990-05-29 | 1996-01-15 | Boston Ocular Res | Zusammensetzung zur behandlung von dry eye erkrankungen |
US5102670A (en) | 1990-09-14 | 1992-04-07 | Abraham Nader G | Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
EP0546728A3 (en) | 1991-12-13 | 1993-09-08 | Alcon Laboratories Inc | Physiological tear compositions and methods for their preparation |
AU674681B2 (en) | 1992-04-21 | 1997-01-09 | Schepens Eye Research Institute, Inc., The | Ocular androgen therapy in Sjogren's syndrome |
US5290572A (en) | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
US5358706A (en) | 1992-09-30 | 1994-10-25 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5389383A (en) | 1993-06-18 | 1995-02-14 | Allergan, Inc. | Method for treating hypoxia-associated ocular complications |
US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
DK0964690T3 (da) | 1996-10-15 | 2003-10-20 | Liposome Co Inc | Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6281192B1 (en) | 1999-03-01 | 2001-08-28 | Vista Scientific Llc | Mucin containing ophthalmic preparations |
-
2000
- 2000-10-23 DE DE60019322T patent/DE60019322T2/de not_active Expired - Fee Related
- 2000-10-23 AT AT00971016T patent/ATE292464T1/de not_active IP Right Cessation
- 2000-10-23 KR KR1020027004594A patent/KR20020040848A/ko not_active Application Discontinuation
- 2000-10-23 CA CA002386623A patent/CA2386623A1/en not_active Abandoned
- 2000-10-23 ES ES00971016T patent/ES2235966T3/es not_active Expired - Lifetime
- 2000-10-23 CN CN00814647A patent/CN1382046A/zh active Pending
- 2000-10-23 JP JP2001536129A patent/JP2003513910A/ja not_active Withdrawn
- 2000-10-23 PL PL00356092A patent/PL356092A1/xx not_active Application Discontinuation
- 2000-10-23 PT PT00971016T patent/PT1227809E/pt unknown
- 2000-10-23 AU AU80315/00A patent/AU776258B2/en not_active Ceased
- 2000-10-23 MX MXPA02004702A patent/MXPA02004702A/es active IP Right Grant
- 2000-10-23 WO PCT/US2000/029235 patent/WO2001034129A2/en active IP Right Grant
- 2000-10-23 TR TR2002/01249T patent/TR200201249T2/xx unknown
- 2000-10-23 BR BR0015423-7A patent/BR0015423A/pt not_active IP Right Cessation
- 2000-10-23 US US09/694,129 patent/US6331566B1/en not_active Expired - Fee Related
- 2000-10-23 EP EP00971016A patent/EP1227809B1/en not_active Expired - Lifetime
- 2000-11-08 TW TW089123629A patent/TWI268776B/zh not_active IP Right Cessation
- 2000-11-08 TW TW095131568A patent/TW200718423A/zh unknown
- 2000-11-08 AR ARP000105867A patent/AR031536A1/es not_active Application Discontinuation
-
2001
- 2001-06-25 US US09/891,357 patent/US6436994B2/en not_active Expired - Lifetime
- 2001-06-25 US US09/891,358 patent/US6441035B2/en not_active Expired - Lifetime
-
2002
- 2002-03-20 ZA ZA200202278A patent/ZA200202278B/en unknown
- 2002-09-14 HK HK02106762.1A patent/HK1045260B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60019322D1 (de) | 2005-05-12 |
US20020002196A1 (en) | 2002-01-03 |
HK1045260B (zh) | 2005-06-10 |
CN1382046A (zh) | 2002-11-27 |
PT1227809E (pt) | 2005-06-30 |
CA2386623A1 (en) | 2001-05-17 |
ES2235966T3 (es) | 2005-07-16 |
AU776258B2 (en) | 2004-09-02 |
AU8031500A (en) | 2001-06-06 |
EP1227809A2 (en) | 2002-08-07 |
EP1227809B1 (en) | 2005-04-06 |
MXPA02004702A (es) | 2004-09-10 |
WO2001034129A3 (en) | 2001-12-13 |
US6331566B1 (en) | 2001-12-18 |
US6436994B2 (en) | 2002-08-20 |
JP2003513910A (ja) | 2003-04-15 |
DE60019322T2 (de) | 2005-09-08 |
TWI268776B (en) | 2006-12-21 |
PL356092A1 (en) | 2004-06-14 |
ZA200202278B (en) | 2003-05-28 |
US6441035B2 (en) | 2002-08-27 |
WO2001034129A2 (en) | 2001-05-17 |
KR20020040848A (ko) | 2002-05-30 |
TW200718423A (en) | 2007-05-16 |
US20010051648A1 (en) | 2001-12-13 |
HK1045260A1 (en) | 2002-11-22 |
TR200201249T2 (tr) | 2002-09-23 |
BR0015423A (pt) | 2002-07-09 |
ATE292464T1 (de) | 2005-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035365A1 (es) | Compuesto peptidico que comprende un centro inhibidor de la metionina aminopeptidasa 2 (metap-2) y su uso para preparar un medicamento | |
AR031536A1 (es) | Analogos heteroatomo- interrumpidos del acido 15-hidroxieicosatetraenoico, composicion que lo comprende y el uso de los mismos para la manufactura de un medicamento | |
UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
ES539658A0 (es) | Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados | |
AR003453A1 (es) | Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores | |
NZ303251A (en) | Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy | |
DOP2005000071A (es) | "compuestos de metil-aril o heteroaril-amida sustituida" | |
MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
OA08182A (fr) | Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
AR056785A1 (es) | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS | |
CO4810382A1 (es) | Compuestos de indol agentes anti-inflamatorios/analgesicos | |
UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
KR900016197A (ko) | 혈전증 및 혈관경련 질환의 치료에 유용한 인터페닐렌 7-옥사비시클로헵틸 치환 헤테로시클릭 아미드 프로스타글란딘 유사체 | |
SE9904507D0 (sv) | New compounds | |
ES2053668T3 (es) | Derivados de poliamina como agentes antineoplasicos. | |
AR034398A1 (es) | Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento | |
OA08715A (fr) | Nouveaux dérivés peptidiques à structure polyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
HUP0302970A2 (hu) | Aminosavak felhasználása fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
PT643061E (pt) | Novos antibioticos de cefalosporina e processos para a sua preparacao | |
AR018675A1 (es) | Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento. | |
ES2032985T3 (es) | Nuevos tripeptidos de estructura policiclica nitrogenada, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
AR013538A1 (es) | Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos | |
AR029769A1 (es) | Analogos de acido hidroxieicosatetraenoico, una composicion para el tratamiento del ojo seco en humanos,y el uso de los mismos para la manufactura de un medicamento | |
ATE223907T1 (de) | Arginnin analoge mit no- syntax inhibierenderwirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |